 ¿La interacción entre el tratamiento hormonal post-menopáusico sustitutivo con los factores de riesgo conocidos aumenta el riesgo de cáncer de mama? |
 |
Ursin G, Tseng C, Paganini-Hill A, Enger S, Wan PC, Formenti S, Pike MC, Ross RK
Does Menopausal Hormone Replacement Therapy Interact With Known Factors to Increase Risk of Breast Cancer?.
J Clin Oncol. 2002 Feb 1;20(3):699-706
|
|
| |
| Frecuencia de las mutaciones BRCA1 y BRCA2 en las mujeres valoradas de riesgo de cáncer de mama |
|
Shih HA, Couch FJ, Nathanson KL, Blackwood MA, Rebbeck TR, Armstrong KA, Calzone K, Stopfer J, Seal S, Stratton MR, Weber BL
BRCA1 and BRCA2 Mutation Frequency in Women Evaluated in a Breast Cancer Risk Evaluation Clinic.
J Clin Oncol. 2002 Feb 15;20(4):994-9
|
|
| |
| Pronóstico de la cirugía preventiva y del screening en portadoras de mutaciones del gen BRCA |
|
Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P, Norton L, Offit K
Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers.
J Clin Oncol. 2002 Mar 1;20(5):1260-8
|
|
| |
| Comunicación entre los médicos y las mujeres ancianas con un cáncer de mama |
|
Liang W, Burnett CB, Rowland JH, Meropol NJ, Eggert L, Hwang Y-T, Silliman RA, Weeks JC, Mandelblatt JS
Communication Between Physicians and Older Women With Localized Breast Cancer: Implications for Treatment and Patient Satisfaction.
J Clin Oncol. 2002 Feb 15;20(4):1008-16
|
|
| |
| Patología coronaria tras radioterapia por cáncer de mama precoz |
|
Vallis KA, Pintilie M, Chong N, Holowaty E, Douglas PS, Kirkbride P, Wielgosz A
Assessment of Coronary Heart Disease Morbidity and Mortality After Radiation Therapy for Early Breast Cancer.
J Clin Oncol. 2002 Feb 15;20(4):1036-42
|
|
| |
| Alteraciones cardíacas en los ensatos clínicos con Trastuzumab |
|
Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience.
J Clin Oncol. 2002 Mar 1;20(5):1215-21
|
|
| |
| Trastuzumab como tratamiento de primera línea en el cáncer de mama metastásico |
|
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.
J Clin Oncol. 2002 Feb 1;20(3):719-26
|
|
| |
| Quimioterapia a altas dósis vs estándar en el tratamiento del cáncer de mama metastásico |
|
Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J, Costanza M, Freytes CO, Stadtmauer E , Gale RP, Henderson IC, Hillard M. Lazarus, McCarthy Jr PL, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, Horowitz MM
High-Dose Versus Standard Chemotherapy in Metastatic Breast Cancer: Comparison of Cancer and Leukemia Group B Trials With Data From the Autologous Blood and Marrow Transplant Registry.
J Clin Oncol 2002 Feb 1;20(3):743-50
|
|
| |
| Modelo pronótico de las recidivas tras quimioterapia a altas dosis por cáncer de mama estadio IV |
|
Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA, Barón A, Razook C, Matthes S, Bearman SI
Prognostic Model for Relapse After High-Dose Chemotherapy With Autologous Stem-Cell Transplantation for Stage IV Oligometastatic Breast Cancer.
J Clin Oncol. 2002 Feb 1;20(3):707-18
|
|
| |
| Quimioterapia polifarmacológica en el cáncer de mama precoz (Revisión Cochrane) |
|
Early Breast Cancer Trialists' Collaborative Group
Multi-agent chemotherapy for early breast cancer (Cochrane Review).
Cochrane Database Syst Rev 2002;CD000487
|
|
| |
| Bifosfonatos en el cáncer de mama (Revisión Cochrane) |
|
Pavlakis N, Stockler M
Bisphosphonates for breast cancer (Cochrane Review).
Cochrane Database Syst Rev 2002;(1):CD003474
|